Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
Treatment and management of aplastic anemia require a coordinated approach that balances curative intent with supportive care. This page is designed for patients and families who are navigating a diagnosis of aplastic anemia and are seeking clear, evidence‑based guidance on therapeutic pathways. According to recent hematology registries, approximately 2–3 cases per million people are diagnosed each year, underscoring the rarity yet seriousness of the condition.
At Liv Hospital, our multidisciplinary team evaluates each case individually, offering personalized treatment and management plans that may include immunosuppressive therapy, stem cell transplantation, and comprehensive supportive measures. Whether you are considering an overseas medical journey or looking for a second opinion, the information below outlines the full spectrum of options, diagnostic steps, and long‑term monitoring strategies.
Understanding the disease, recognizing when to intervene aggressively, and maintaining vigilant follow‑up are all integral components of successful treatment and management. Below, we break down each element in detail to help you make informed decisions.
Aplastic anemia is a bone‑marrow failure syndrome characterized by pancytopenia and a hypocellular marrow. The condition can be acquired or inherited, and identifying the underlying cause is essential for tailoring treatment and management strategies.
Recognizing these triggers guides the selection of appropriate treatment and management pathways, ensuring that therapy addresses the root cause whenever possible.
Accurate diagnosis lays the foundation for effective treatment and management. A thorough work‑up includes clinical assessment, laboratory studies, and marrow examination.
These assessments enable clinicians at Liv Hospital to design a precise treatment and management plan, aligning therapeutic intensity with disease severity.
For most adult patients without a suitable donor, the cornerstone of treatment and management is immunosuppressive therapy (IST) combined with supportive care. The choice between IST and immediate transplantation depends on age, severity, and donor availability.
Choosing the appropriate first‑line approach is a pivotal element of comprehensive treatment and management, and our hematology specialists tailor therapy to each patient’s unique profile.
Allogeneic hematopoietic stem cell transplantation (HSCT) offers the only potential cure for severe aplastic anemia, especially in younger patients or those with a matched donor.
Liv Hospital’s transplant unit follows international JCI standards, providing a seamless continuum from donor search to post‑transplant rehabilitation, forming a core component of the overall treatment and management plan.
Even after successful therapy, lifelong surveillance is essential to detect relapse, late complications, and secondary malignancies. A structured follow‑up schedule is integral to the comprehensive treatment and management of aplastic anemia.
Patients are also encouraged to engage in psychosocial support programs, nutritional counseling, and regular exercise, all of which complement medical treatment and management and improve long‑term outcomes.
Liv Hospital combines JCI accreditation with a dedicated International Patient Services team, ensuring that every aspect of your treatment and management journey is coordinated—from visa assistance to post‑procedure follow‑up. Our hematology department leverages state‑of‑the‑art laboratory facilities, experienced transplant surgeons, and personalized care plans tailored to the needs of patients traveling from abroad.
Ready to discuss your personalized treatment plan? Contact Liv Hospital today to schedule a confidential consultation with our hematology experts. Experience world‑class care designed for international patients, with comprehensive support every step of the way.
Send us all your questions or requests, and our expert team will assist you.
For most adult patients without a suitable donor, immunosuppressive therapy (IST) is the cornerstone of first‑line treatment. IST typically includes antithymocyte globulin (ATG) to deplete activated T‑cells, cyclophosphamide as an alkylating agent, and corticosteroids to reduce cytokine release. Eltrombopag, a thrombopoietin receptor agonist, may be added to boost platelet production. Supportive measures—red blood cell and platelet transfusions, broad‑spectrum antibiotics for neutropenic fever, and growth factor support (G‑CSF)—are used concurrently to manage cytopenias and prevent infections. Response rates for IST range from 60‑70% with a 5‑year survival of 70‑80%.
Allogeneic hematopoietic stem cell transplantation (HSCT) offers the only potential cure for severe aplastic anemia. Eligibility criteria include age ≤40‑45 years (optimal outcomes), life‑threatening pancytopenia, and availability of an HLA‑matched sibling or unrelated donor. Patients must also be free of uncontrolled infections and have adequate organ function. Matched sibling donors provide the best 5‑year survival (80‑85%), while matched unrelated donors yield 70‑75% and haploidentical donors 60‑65%. The transplant process involves conditioning, stem‑cell infusion, post‑transplant immunosuppression, and long‑term monitoring.
A thorough work‑up begins with a CBC with differential to document low hemoglobin, neutrophils, and platelets, followed by a reticulocyte count that typically shows decreased production. Bone‑marrow aspirate and biopsy are essential to demonstrate cellularity below 30% and to exclude infiltrative diseases. Additional serologic testing for hepatitis B/C, HIV, and parvovirus B19 helps identify infectious triggers. For suspected inherited syndromes, chromosomal breakage tests (e.g., for Fanconi anemia) are performed. These investigations guide the choice between immunosuppression and transplantation.
Supportive care aims to maintain adequate oxygen‑carrying capacity and hemostasis while preventing infections. Red blood cell transfusions keep hemoglobin above 8 g/dL; platelet transfusions are given when counts fall below 10 × 10⁹/L or bleeding risk is high. Broad‑spectrum antibiotics are started promptly for neutropenic fever. Iron overload from chronic transfusions is monitored with serum ferritin and managed with chelation therapy. Granulocyte‑colony stimulating factor (G‑CSF) may be used to stimulate neutrophil recovery in selected cases. Psychosocial support, nutritional counseling, and exercise programs further enhance recovery.
Post‑treatment surveillance follows a structured schedule. During the first three months, patients have monthly visits with CBC, physical exam, and review of transfusion needs. From months four to twelve, labs are obtained every two months, including iron studies and organ function tests. After the first year, annual evaluations include CBC, ferritin, renal and hepatic panels, and, if indicated, a repeat bone‑marrow biopsy to assess engraftment or detect relapse. Ongoing assessments also track quality‑of‑life, psychosocial status, and screen for secondary malignancies.
Candidates for allogeneic HSCT are evaluated on several criteria. Younger age (generally ≤40‑45 years) correlates with better outcomes. Disease severity is assessed by the degree of pancytopenia and presence of life‑threatening complications such as severe bleeding or infections. A suitable donor—preferably an HLA‑matched sibling, but also a matched unrelated or haploidentical donor—must be identified. Patients must be free of uncontrolled infections and have adequate cardiac, pulmonary, hepatic, and renal function to tolerate conditioning regimens. These factors together guide the transplant team’s decision to proceed with HSCT.
Your Comparison List (you must select at least 2 packages)
